Results 61 to 70 of about 2,849,098 (354)

Nano drug delivery systems for advanced immune checkpoint blockade therapy

Theranostics
Immune checkpoint inhibitors (ICIs) have been widely utilized in the first-line therapy of various types of cancer. However, immune-related adverse events (irAEs) and resistance to ICIs remain intractable challenges for immune checkpoint blockade (ICB ...
Chenqi Guo, Ling Lin, Yihan Wang, Jing Jing, Qiyong Gong, Kui Luo   +5 more
semanticscholar   +1 more source

Real‐World Pediatric Blinatumomab Administration: Access to Outpatient Care Delivery and Impact of a Hospital‐Dispensed Model

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Blinatumomab has been shown to be highly effective for patients with pediatric B‐ALL and has recently become standard of care therapy. Due to its past use in the clinical trial setting, there is limited information available about real‐world administration.
Katelyn Oranges, Kelly A. Duffy, Sara McDonough, Evelyn Kurpiewski, R. Jennifer Randall, Allison Barz Leahy, Haley M. Newman, Joyce P. Lee, Stephen P. Hunger, Anne F. Reilly, David T. Teachey, Susan R. Rheingold, Daniel J. Zheng   +12 more
wiley   +1 more source

The relation between submaximal aerobic exercise improving vascular elasticity through loss of visceral fat and antihypertensive

Clinical and Experimental Hypertension, 2021
Purpose: We sought to observe the effect of submaximal aerobic exercise on abdominal obesity in hypertension patients and to clarify a correlation between blood pressure improvement and visceral fat, along with arterial elasticity. Materials and Methods:
Hong Fang, Chi Liu, Omer Cavdar
doaj   +1 more source

Quantifying the pharmacology of antimalarial drug combination therapy. [PDF]

, 2016
Most current antimalarial drugs are combinations of an artemisinin plus a 'partner' drug from another class, and are known as artemisinin-based combination therapies (ACTs). They are the frontline drugs in treating human malaria infections.
Hodel, Eva Maria
core   +1 more source

Targeting KRAS mutant cancers: from druggable therapy to drug resistance

Molecular Cancer, 2022
Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) is the most frequently mutated oncogene, occurring in a variety of tumor types. Targeting KRAS mutations with drugs is challenging because KRAS is considered undruggable due to the lack of classic drug ...
Chunxi Zhu, Xiaoqing Guan, Xinuo Zhang, X. Luan, Zhengbo Song, Xiangdong Cheng, Weidong Zhang, Jiangjiang Qin   +7 more
semanticscholar   +1 more source

Personalized Selumetinib Dosing in Pediatric Neurofibromatosis Type 1: Insights From a Pilot Therapeutic Drug Monitoring Study

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Objective To evaluate selumetinib exposure using therapeutic drug monitoring (TDM) in pediatric patients with neurofibromatosis type 1 (NF1) and plexiform neurofibromas (PN), assess interpatient pharmacokinetic variability, and explore the relationship between drug exposure, clinical response, and adverse effects.
Janka Kovács, Zoltán Köllő, Balázs Gellért Karvaly, Mahmoud Obeidat, Rita Nagy, Péter Hegyi, Brigitta Teutsch, Eszter Tuboly, Miklós Garami   +8 more
wiley   +1 more source

Analysis of Combination Drug Therapy to Develop Regimens with Shortened Duration of Treatment for Tuberculosis

PLoS ONE, 2014
Rationale Tuberculosis remains a worldwide problem, particularly with the advent of multi-drug resistance. Shortening therapy duration for Mycobacterium tuberculosis is a major goal, requiring generation of optimal kill rate and resistance-suppression ...
G. Drusano, M. Neely, M. van Guilder, A. Schumitzky, David Brown, Steven Fikes, C. Peloquin, A. Louie   +7 more
semanticscholar   +1 more source

Adherence to Protocol Recommendations for Children With Wilms Tumour in Two Consecutive Studies in the United Kingdom and Ireland—Does Variation Matter?

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background and Aims Wilms tumour (WT) has excellent event‐free and overall survival (OS). However, small differences exist between countries participating in the same international study. This led us to examine variation in adherence to protocol recommendations as a potential contributing factor.
Suzanne Tugnait, R. Al‐Saadi, A. Lopez‐Cortes, K. Dzhuma, M. Oostveen, J. Brok, S. Irtan, M. Weeks, J. Bate, S. Baker, R. Williams, M. Powis, D. Saunders, O. Olsen, T. Watson, S. Shelmerdine, S. Vaidya, L. Howell, C. Duncan, G. M. Vujanic, C. Stiller, G. P. Balchin, T. Chowdhury, K. Pritchard‐Jones   +23 more
wiley   +1 more source

Giant cells lepromatous leprosy. Diffuse dermatitis with exuberant foreign body giant cells in treated lepromatous leprosy

Biomédica: revista del Instituto Nacional de Salud, 2019
Patients with lepromatous leprosy that have received treatment for many years usually get follow up biopsies for persistent skin lesions or positive bacilloscopy even if the values are lower than in the initial bacilloscopy.
Gerzaín Rodríguez, Viviana Arias
doaj   +1 more source

Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. [PDF]

, 2012
Drug resistance presents a challenge to the treatment of cancer patients. Many studies have focused on cell-autonomous mechanisms of drug resistance. By contrast, we proposed that the tumour micro-environment confers innate resistance to therapy. Here we
Barzily-Rokni, Michal, Chapman, Paul B, Cooper, Zachary A, Davis, Ashli, Du, Jinyan, Flaherty, Keith T, Frederick, Dennie T, Golub, Todd R, Gould, Joshua, Lo, Roger S, Mongare, Margaret M, Morikawa, Teppei, Ogino, Shuji, Qian, Zhi Rong, Ribas, Antoni, Shee, Kevin, Solit, David B, Straussman, Ravid, Wargo, Jennifer A   +18 more
core   +1 more source